The British journal of ophthalmology · 2014
Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shimura Masahiko, Yasuda Kanako
Аннотация
BACKGROUND/AIMS: To evaluate the effectiveness of topical bromfenac during treatment with intravitreal injections of bevacizumab (IVB) in eyes with macular oedema (ME) secondary to branch retinal vein occlusion (BRVO).
METHODS: Prospective interventional case-control study. 48 eyes of 44 patients with ME-BRVO who received 1.25 mg/0.05 mL of IVB showed temporary regression of ME. Additional IVB were given when ME recurred. 24 eyes received topical bromfenac, and the other 24 eyes received topical saline as control, four times a day during the clinical course of 48 weeks. The clinical course of foveal thickness (FT) as measured by optical coherence tomography, logarithm of the minimum angle of resolution visual acuity (VA), was monitored. The number of IVB was also recorded.
RESULTS: There were no significant differences in FT, VA between the bromfenac-treated eyes and the control eyes at the initial and final examinations. The number of injections in bromfenac-treated eyes of 3.8±1.1 times was significantly less than in the control eyes of 4.8±1.2 times.
CONCLUSIONS: Although topical bromfenac during IVB therapy in eyes with ME secondary to BRVO did not affect the visual prognosis, it had the advantage of reducing the number of injections.
TRIAL REGISTRATION NUMBER: UMIN 14929.
METHODS: Prospective interventional case-control study. 48 eyes of 44 patients with ME-BRVO who received 1.25 mg/0.05 mL of IVB showed temporary regression of ME. Additional IVB were given when ME recurred. 24 eyes received topical bromfenac, and the other 24 eyes received topical saline as control, four times a day during the clinical course of 48 weeks. The clinical course of foveal thickness (FT) as measured by optical coherence tomography, logarithm of the minimum angle of resolution visual acuity (VA), was monitored. The number of IVB was also recorded.
RESULTS: There were no significant differences in FT, VA between the bromfenac-treated eyes and the control eyes at the initial and final examinations. The number of injections in bromfenac-treated eyes of 3.8±1.1 times was significantly less than in the control eyes of 4.8±1.2 times.
CONCLUSIONS: Although topical bromfenac during IVB therapy in eyes with ME secondary to BRVO did not affect the visual prognosis, it had the advantage of reducing the number of injections.
TRIAL REGISTRATION NUMBER: UMIN 14929.
Предметные рубрики MeSH
Administration, TopicalAgedAngiogenesis InhibitorsAnti-Inflammatory Agents, Non-SteroidalAntibodies, Monoclonal, HumanizedBenzophenonesBevacizumabBromobenzenesCase-Control StudiesFemaleHumansIntravitreal InjectionsMacular EdemaMaleMiddle AgedOphthalmic SolutionsProspective StudiesRetinal Vein OcclusionRetreatmentVascular Endothelial Growth Factor AVisual AcuityVisual Fields